Robert Bast

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint A genetically defined model for human ovarian cancer
    Jinsong Liu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:1655-63. 2004
  2. ncbi request reprint Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Clin Cancer Res 10:3919-26. 2004
  3. ncbi request reprint Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
  4. ncbi request reprint Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer
    Zendra Lee
    Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer Res 66:2740-8. 2006
  5. pmc Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women s Oncology, Women s and Infants Hospital, Providence, RI 02905, USA
    Gynecol Oncol 106:490-7. 2007
  6. pmc Early detection of ovarian cancer
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Dis Markers 23:397-410. 2007
  7. pmc Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome
    Jia Xu
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BMC Cancer 12:243. 2012
  8. pmc Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer
    Robert C Bast
    Department of Experimental Therapeutics and Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 2:16-8. 2012
  9. pmc Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers
    Robert C Bast
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Gynecol Cancer 22:S5-8. 2012
  10. pmc Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy
    Ignacio Romero
    M D Anderson Cancer Center, Translational Research, Houston, Texas 77030, USA
    Endocrinology 153:1593-602. 2012

Detail Information

Publications90

  1. ncbi request reprint A genetically defined model for human ovarian cancer
    Jinsong Liu
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:1655-63. 2004
    ..These cells provide a novel model system to study human ovarian cancer...
  2. ncbi request reprint Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Clin Cancer Res 10:3919-26. 2004
  3. ncbi request reprint Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy
    Lynn C Hartmann
    Mayo Clinic Cancer Center, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 11:2149-55. 2005
    ..We hypothesized that differences in gene expression before treatment could distinguish patients with short versus long time to recurrence after administration of platinum-paclitaxel combination chemotherapy...
  4. ncbi request reprint Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer
    Zendra Lee
    Department of Biochemistry, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer Res 66:2740-8. 2006
    ..The effect of serum on GROalpha production is also significantly decreased by siRNA inhibition of LPA(2) expression. These studies identify LPA as a primary regulator of GROalpha expression in ovarian cancer...
  5. pmc Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, and Program in Women s Oncology, Women s and Infants Hospital, Providence, RI 02905, USA
    Gynecol Oncol 106:490-7. 2007
    ..Mesothelin has been detected in serum from patients with ovarian cancer, but has not been previously reported in urine...
  6. pmc Early detection of ovarian cancer
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Dis Markers 23:397-410. 2007
    ..The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise...
  7. pmc Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome
    Jia Xu
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    BMC Cancer 12:243. 2012
    ..To determine the impact of methylation on clinical outcome, we have conducted a larger study with breast cancers for which time to first recurrence and overall survival are known...
  8. pmc Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer
    Robert C Bast
    Department of Experimental Therapeutics and Systems Biology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer Discov 2:16-8. 2012
    ..Inhibition of multiple signaling pathways will likely be required to achieve effective personalized therapy for patients whose cancers exhibit "PI3Kness."..
  9. pmc Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers
    Robert C Bast
    University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Gynecol Cancer 22:S5-8. 2012
    ..Both algorithms have high negative predictive values 94%-98%. Although a difference in specificity should not affect patient outcomes, it could affect distribution of medical resources...
  10. pmc Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy
    Ignacio Romero
    M D Anderson Cancer Center, Translational Research, Houston, Texas 77030, USA
    Endocrinology 153:1593-602. 2012
    ..Both in silico and animal models are needed that more closely resemble type I and type II cancers to facilitate the identification of novel targets and to predict response to combinations of new agents...
  11. pmc Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010
    ..The primary endpoints were objective response rate (ORR) and progression-free survival (PFS)...
  12. pmc A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer
    Ahmed Ashour Ahmed
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 422, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 68:1033-44. 2011
    ..To investigate the mechanistic basis of the anti-tumor effect of the compound ITB-301...
  13. pmc Correlation between CpG methylation profiles and hormone receptor status in breast cancers
    Weiwei Feng
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res 9:R57. 2007
    ..The present study was undertaken to determine whether methylation of a set of growth-suppressor genes would correlate to the expression of estrogen receptors (ERs) and progesterone receptors (PRs)...
  14. pmc Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel
    Chun Fang Zou
    Department of Gynecology, Obstetrics and Gynecology, Hospital of Fudan University, Shanghai 200011, PR China
    BMC Cancer 11:22. 2011
    ..The purpose of this study is to examine whether ARHI induces autophagy in breast cancer cells and to evaluate the effects of ARHI gene re-expression in combination with paclitaxel...
  15. pmc Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers
    Weiwei Feng
    Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
    BMC Cancer 10:378. 2010
    ..This study is to investigate the status and role of methylation in lymph node metastatic tumors...
  16. pmc Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel
    Ahmed Ashour Ahmed
    Department of Experimental Therapeutics, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Cancer Res 71:5806-17. 2011
    ..Our results offer a functional classification of the genetic basis for paclitaxel sensitivity and they support the hypothesis that stabilizing microtubules prior to therapy could enhance antitumor responses to paclitaxel treatment...
  17. ncbi request reprint Status of tumor markers in ovarian cancer screening
    Robert C Bast
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 21:200s-205s. 2003
    ..At present, screening women at conventional risk should be restricted to clinical trials. In the future, however, screening for ovarian cancer may reduce the morbidity and mortality of this disease...
  18. ncbi request reprint Translational crossroads for biomarkers
    Robert C Bast
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6103-8. 2005
    ....
  19. pmc The biology of ovarian cancer: new opportunities for translation
    Robert C Bast
    Departments of Experimental Therapeutics and Systems Biology, University of Texas M D Anderson Cancer Center, 1515 Holcolmbe Boulevard, Houston, TX 77030, USA
    Nat Rev Cancer 9:415-28. 2009
    ....
  20. ncbi request reprint New tumor markers: CA125 and beyond
    R C Bast
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 15:274-81. 2005
    ..In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer...
  21. doi request reprint Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation
    Weiwei Feng
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 112:1489-502. 2008
    ..Two imprinted genes, paternally expressed 3 (PEG3) and aplasia Ras homologue member I (ARHI), are the most frequently down-regulated in ovarian cancers on gene expression arrays...
  22. ncbi request reprint In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer
    Molly Brewer
    Department of Gynecologic Oncology, University of Texas, The M D Anderson Cancer Center, Houston, TX 77030, USA
    Gynecol Oncol 98:182-92. 2005
    ..However, the effectiveness of its application for different populations has been questioned because of the genetic differences among normal, high risk, and women with cancer...
  23. ncbi request reprint Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway
    Jia Ju Bao
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:7264-72. 2002
    ..Consequently, reexpression of ARHI in breast and ovarian cancer cells appears to induce apoptosis through a caspase-independent, calpain-dependent mechanism...
  24. ncbi request reprint Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
    Karen H Lu
    Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3291-300. 2004
    ..Consequently, use of multiple markers in combination might detect a larger fraction of early-stage ovarian cancers...
  25. ncbi request reprint Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer
    Zhen Lu
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 12:2404-13. 2006
    ..Our previous reports indicated that ARHI promoter activity was reduced in ovarian cancer cells, due in part to the effects of negative regulatory transcription factor(s). Experimental Design and..
  26. ncbi request reprint Potential markers that complement expression of CA125 in epithelial ovarian cancer
    Daniel G Rosen
    Department of Pathology, University of Texas M D Anderson Cancer Center, Box 355, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 99:267-77. 2005
    ..Serum tumor markers that can be detected in ovarian cancers that lack CA125 expression might improve the sensitivity for early detection...
  27. ncbi request reprint Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway
    Xiao Feng Le
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cell Cycle 5:1654-61. 2006
    ....
  28. ncbi request reprint Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling
    Xiao Feng Le
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 280:2092-104. 2005
    ..Transcriptional regulation by anti-HER2 antibody through PI3K-AKT pathway may potentiate the growth inhibitory activity of docetaxel by affecting cell cycle progression...
  29. pmc Stanniocalcin 1 and ovarian tumorigenesis
    Guangzhi Liu
    Department of Pathology, Unit 85, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Natl Cancer Inst 102:812-27. 2010
    ..Stanniocalcin 1 (STC1) is a secreted glycoprotein hormone. High expression of STC1 has been associated with several cancers including ovarian cancer, but its role in the development of ovarian cancer is not clear...
  30. ncbi request reprint Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers
    Jiuhong Yuan
    Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 63:4174-80. 2003
    ..Other epigenetic modifications such as hypermethylation in CpG island III may also contribute to the loss of ARHI expression...
  31. ncbi request reprint Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop
    Robert C Bast
    M D Anderson Cancer Center, Houston, TX, USA
    Gynecol Oncol 107:173-6. 2007
    ....
  32. ncbi request reprint Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer
    Janos L Tanyi
    Departments of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:3534-45. 2003
    ..Thus, the LPA-rich environment of the ovarian cancer cell in vivo and the subsequent effects of cellular pathophysiology may be a consequence of both increased LPA production and decreased LPA metabolism by ovarian cancer cells...
  33. ncbi request reprint Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression
    Gong Yang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    J Biol Chem 279:4339-45. 2004
    ..siRNA-mediated gene silencing of Her-2/neu and increasing the expression of thrombospondin-1 may be a useful therapeutic strategy for Her-2/neu-over-expressing breast or ovarian cancer...
  34. ncbi request reprint Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer
    Lin Wang
    Departments of Experimental Therapeutics L W, R Z L, J Y, Z L, A N, R C B, Y Y, Clinical Cancer Prevention A H, S M L, and Pathology J L, A A S, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030
    Clin Cancer Res 9:3660-6. 2003
    ..This study investigated the relationship of ARHI expression to the progression of breast cancer...
  35. ncbi request reprint Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells
    Xiao Feng Le
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Mol Cancer Ther 6:2843-57. 2007
    ..The negative effects of cyclin G2 on cell cycle and cell proliferation, which occur without altering p27(Kip1) levels, may contribute to the ability of trastuzumab to inhibit breast cancer cell growth...
  36. ncbi request reprint Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival
    Daniel G Rosen
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6559-66. 2004
    ..To determine the relevance of these observations to clinical cancer, we have now measured ARHI expression in normal, benign and malignant ovarian tissues using immunohistochemistry and in situ hybridization...
  37. ncbi request reprint Targeting Aurora kinases in ovarian cancer
    Siqing Fu
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, PO Box 301439, Houston, Texas 77230 1439, USA
    Expert Opin Ther Targets 10:77-85. 2006
    ..The authors propose that Aurora kinase inhibitors be developed as molecular therapeutic agents in order to minimise their toxicities and maximise their antitumour activities for ovarian cancer treatment...
  38. pmc A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies
    Violeta G Hennessey
    Department of Biostatistics, The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biometrics 66:1275-83. 2010
    ....
  39. pmc Dasatinib induces autophagic cell death in human ovarian cancer
    Xiao Feng Le
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 116:4980-90. 2010
    ..Dasatinib, an inhibitor of Src/Abl family kinases, can inhibit tumor growth of several solid tumors. However, the effect and mechanism of action of dasatinib in human ovarian cancer cells remains unknown...
  40. ncbi request reprint Prevention and early detection of ovarian cancer: mission impossible?
    Robert C Bast
    M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Recent Results Cancer Res 174:91-100. 2007
    ..In the future, serum markers should improve the sensitivity of detecting recurrent disease as well as facilitate earlier detection of ovarian cancer...
  41. pmc Early detection of ovarian cancer
    Partha M Das
    University of Texas, MD Anderson Cancer Center, Department of Experimental Therapeutics, Houston, TX, USA
    Biomark Med 2:291-303. 2008
    ..In this review, we will assess the current status and describe future directions in ovarian cancer screening...
  42. ncbi request reprint Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells
    Gong Yang
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 28:174-82. 2007
    ....
  43. pmc Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment
    Jingfang Zheng
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cell Cycle 9:140-6. 2010
    ....
  44. ncbi request reprint Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers
    Yinhua Yu
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Methods Enzymol 407:455-68. 2006
    ..Growth of ovarian and breast cancer xenografts is reversibly suppressed by ARHI, but expression of the NTD mutant produced only a limited inhibitory effect on growth of xenografts...
  45. ncbi request reprint A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells
    Arata Nishimoto
    Department of Experimental Therapeutics, Biochemistry and Molecular Biology, Immunology, and Molecular Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 65:6701-10. 2005
    ....
  46. ncbi request reprint Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon
    Rebecca T Marquez
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:6116-26. 2005
    ..This study compares gene expression in serous, endometrioid, clear cell, and mucinous ovarian cancers with that in the normal tissues that they resemble...
  47. pmc Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2
    Xiao Feng Le
    Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cell Cycle 7:3747-58. 2008
    ..Similar mechanisms may contribute to the clinical anti-tumor activity of trastuzumab in combination with inhibitors of VEGF signaling pathway in women with breast cancers which overexpress HER2...
  48. ncbi request reprint Epigenetic regulation of ARHI in breast and ovarian cancer cells
    Yinhua Yu
    Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann N Y Acad Sci 983:268-77. 2003
    ..Reactivation of both the silenced paternal and imprinted maternal alleles can be achieved by demethylation and inhibition of histone deacetylation...
  49. ncbi request reprint Overexpression of kallikrein 10 in epithelial ovarian carcinomas
    Hyun S Shvartsman
    Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Gynecol Oncol 90:44-50. 2003
    ..We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma...
  50. ncbi request reprint Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation
    Satoshi Fujii
    Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Hum Mol Genet 12:1791-800. 2003
    ....
  51. ncbi request reprint ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers
    Robert Z Luo
    Department of Experimental Therapeutics, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncogene 22:2897-909. 2003
    ..Furthermore, unlike the Ras oncogene, ARHI inhibits cell growth, and loss of its expression in cells may contribute to the development of breast and ovarian cancers...
  52. doi request reprint Project Zero Delay: a process for accelerating the activation of cancer clinical trials
    Razelle Kurzrock
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, Division of Cancer Medicine, M D Anderson Cancer Center, Unit 455, PO Box 301402 Houston, TX 77030, USA
    J Clin Oncol 27:4433-40. 2009
    ..Eliminating administrative delays can accelerate the evaluation of new drugs without compromising patient safety or the quality of clinical research...
  53. pmc The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells
    Zhen Lu
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Clin Invest 118:3917-29. 2008
    ..Thus, ARHI can induce autophagic cell death, but can also promote tumor dormancy in the presence of factors that promote survival in the cancer microenvironment...
  54. pmc Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
    Siqing Fu
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1661-9. 2011
    ..A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer...
  55. ncbi request reprint HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways
    Xiao Feng Le
    Department of Experimental Therapeutics, Division of Cancer Medicine, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cell Cycle 4:87-95. 2005
    ..The targets and pathways affected by trastuzumab work in concert to maximize the expression and inhibitory effect of p27Kip1, which leads to cell cycle G1 arrest and growth inhibition...
  56. ncbi request reprint Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer
    Daniel G Rosen
    Departments of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 11:632-7. 2005
    ....
  57. ncbi request reprint Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer
    Daniel G Rosen
    The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Methods Enzymol 407:660-76. 2006
    ....
  58. pmc Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers
    Yongkun Wei
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Carcinog 47:701-6. 2008
    ..These results suggest that H3K27me3 expression is a prognostic indicator for clinical outcome in patients with breast, ovarian, and pancreatic cancers...
  59. pmc MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse
    Ying Wang
    Department of Molecular Genetics, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Differentiation 76:1081-92. 2008
    ..These findings document the presence of MUC16 in murine ovarian cancer and in normal tissues and provide a foundation for future functional studies...
  60. pmc ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins
    Shaoyi Huang
    Department of Experimental Therapeutics, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Biosci Rep 30:159-68. 2010
    ..Thus ARHI-induced disruption of importin-binding to cargo proteins, including STAT3, could serve as an important regulatory mechanism that contributes to the tumour-suppressor function of ARHI...
  61. pmc MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma
    Ajoy K Samanta
    Department of Biochemistry and Molecular Biology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:3897-908. 2009
    ..The authors have demonstrated that MEKK3 plays a critical role in cytokine-mediated NFkappaB activation, and that stable expression of MEKK3 in cultured cells leads to increased NFkappaB activity...
  62. ncbi request reprint Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers
    Claire F Verschraegen
    Department of Gynecologic Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:845-52. 2003
    ..The purpose of this study was to characterize cell cultures and xenografts derived from patients with ovarian cancer...
  63. ncbi request reprint The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
    Xiao Feng Le
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 278:23441-50. 2003
    ..Regulation of the phosphorylation of p27Kip1 protein is one of the post-translational mechanisms by which anti-HER2 antibody upregulates the protein...
  64. ncbi request reprint Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer
    Gordon B Mills
    Department of Molecular Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 30:93-104. 2003
    ..This review will focus on the phosphatidylinositol 3-kinase pathway and novel molecules targeting this pathway to illustrate the questions and challenges underlying the implementation of molecular therapeutics in breast cancer...
  65. ncbi request reprint Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB
    Ajoy K Samanta
    Department of Biochemistry and Molecular Biology, Program in Genes and Development, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:7576-83. 2004
    ..As such, MEKK3 may serve as a therapeutic target to control cancer cell resistance to cytokine- or drug-induced apoptosis...
  66. ncbi request reprint Early detection of ovarian cancer: promise and reality
    Robert C Bast
    Departments of Experimental Therapeutics, Molecular Therapeutics, Gynecologic Oncology and Anatomic Pathology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Treat Res 107:61-97. 2002
  67. ncbi request reprint The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis
    Daniel G Rosen
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2730-40. 2006
    ....
  68. pmc A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
    Xiaoming Xie
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2375-82. 2009
    ..v. delivery of T-VISA-E1A:liposomal nanoparticles, suggesting a promising role of T-VISA-E1A for ovarian cancer treatment under a gene therapy setting...
  69. ncbi request reprint Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers
    Jon R Wiener
    Department of Molecular Therapeutics, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Gynecol Oncol 88:73-9. 2003
    ..The objective of this study was to determine if the Src tyrosine kinase is overexpressed and activated in late-stage human ovarian cancers...
  70. pmc CA125/MUC16 is dispensable for mouse development and reproduction
    Dong Joo Cheon
    Program in Genes and Development, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas, USA
    PLoS ONE 4:e4675. 2009
    ..These knockout mice provide a unique platform for future studies to identify the role of CA125/MUC16 in organ homeostasis and ovarian cancer...
  71. ncbi request reprint Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Box 424, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    Cancer Invest 22:248-56. 2004
    ..However, it does not appear to determine response to doxorubicin-based chemotherapy. In contrast, lack of Bcl-2 expression was associated with a higher probability of complete pathological response to doxorubicin-based chemotherapy...
  72. ncbi request reprint Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents
    Molly Brewer
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biomed Opt 7:20-6. 2002
    ..The objective of this study was to compare the effects of chemopreventive agents on natural fluorescence emission of ovarian cells in a cell culture and in a primate model as a feasibility trial to monitor drug activity...
  73. pmc SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer
    Ahmed Ashour Ahmed
    Department of Experimental Therapeutics, M D Anderson Cancer Center, University of Texas, Houston, 77030, USA
    Cancer Cell 18:109-21. 2010
    ..Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers...
  74. ncbi request reprint Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells
    Xianjun Fang
    Department of Molecular Therapeutics, M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Biol Chem 279:9653-61. 2004
    ..These studies elucidate the transcriptional mechanism and the Edg LPA receptors involved in LPA-induced IL-6 and IL-8 production and suggest potential strategies to restrain the expression of these cytokines in ovarian cancer...
  75. pmc The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis
    Gong Yang
    Department of Pathology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 103:16472-7. 2006
    ..Therefore, Gro-1 may be a therapeutic target as well as a diagnostic marker in ovarian cancer...
  76. ncbi request reprint Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms
    Mikihito Nakamori
    Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 9:2727-33. 2003
    ..Zhang, Cancer Res., 62: 2306-2312, 2002; X. Fu et al., Mol. Ther., in press, 2003). We reasoned that both fusogenic strategies, incorporated into a single oncolytic HSV, might significantly improve virotherapy for ovarian cancer...
  77. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  78. ncbi request reprint Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer
    Usha Menon
    Department of Gynecological Oncology, Institute of Women s Health, University College London
    J Clin Oncol 23:7919-26. 2005
    ..To evaluate prevalence screening in the first prospective trial of a new ovarian cancer screening (OCS) strategy (risk of ovarian cancer or ROC algorithm) on the basis of age and CA125 profile...
  79. ncbi request reprint Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
    Steven J Skates
    Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
    J Clin Oncol 22:4059-66. 2004
    ..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)...
  80. ncbi request reprint Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  81. pmc Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model
    Travis Young
    Department of Pharmacology and Toxicology, The University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555 1031, USA
    Oncogene 24:6174-84. 2005
    ..This study demonstrates that functional proteomic analysis of a genetically defined cancer model provides a powerful approach toward systematically identifying cellular targets associated with oncogenic transformation...
  82. ncbi request reprint ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    Gershon Y Locker
    American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
    J Clin Oncol 24:5313-27. 2006
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
  83. ncbi request reprint Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3881-4. 2004
  84. ncbi request reprint American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  85. ncbi request reprint The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  86. ncbi request reprint Individualized care for patients with cancer - a work in progress
    Robert C Bast
    N Engl J Med 351:2865-7. 2004
  87. ncbi request reprint Biomarkers and clinical trial design
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Gynecol Oncol 103:S3-5. 2006
  88. ncbi request reprint How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above
    Richard G Moore
    J Clin Oncol 25:4159-61. 2007
  89. pmc Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer
    Zhen Zhang
    Center for Biomarker Discovery, Department of Pathology, Johns Hopkins Medical Institutions, CRB II 3M04, 1550 Orleans Street, Baltimore, MD 21231, USA
    Gynecol Oncol 107:526-31. 2007
    ..In this paper, an ANN model was evaluated for its performance in detecting early stage epithelial ovarian cancer using multiple serum markers...
  90. pmc Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 110:196-201. 2008
    ..The objectives of this study were to examine the levels of several novel tumor markers HE4, SMRP, CA72.4 and CA125 as potential markers in patients diagnosed with endometrioid adenocarcinoma of the uterus...

Research Grants13

  1. ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer
    Robert C Bast; Fiscal Year: 2010
    ..These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible. ..
  2. ARHI (DIRAS 3) in Autophagy and Dormancy of Ovarian Cancer
    Robert Bast; Fiscal Year: 2009
    ..These studies will test a novel strategy to eliminate dormant ovarian cancer cells by blocking factors required for their survival. If successful, early translation to clinical trials should be feasible. ..
  3. UNIVERSITY OF TEXAS MD ANDERSON SPORE IN OVARIAN CANCER
    Robert Bast; Fiscal Year: 2007
    ..Developmental research and career development programs have been strengthened and extended to other institutions. Perspective will continue to be provided by internal, external and advocate advisors. ..
  4. Paul Calabresi Clinical Oncology Award
    Robert Bast; Fiscal Year: 2007
    ..Each Calabresi scholar is guided by a clinical mentor and a translational mentor as well as the program's Advisory Committee, composed of experts in clinical, laboratory, and translational research. ..
  5. SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES
    Robert Bast; Fiscal Year: 2004
    ....
  6. SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES
    Robert Bast; Fiscal Year: 2003
    ....
  7. SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES
    Robert Bast; Fiscal Year: 2002
    ....
  8. SPECIFIC IMMUNOTHERAPY WITH MONOCLONAL ANTIBODIES
    Robert Bast; Fiscal Year: 2001
    ....